Theratechnologies Inc.: Revenue Growth and Expenditure

Theratechnologies Inc.: Revenue Growth and Expenditure Control at the
Core of Revised Business Plan 
MONTREAL, CANADA -- (Marketwire) -- 10/30/12 -- Theratechnologies
Inc. (TSX:TH) (NASDAQ:THER) today announced its revised business plan
which will focus on revenue growth from tesamorelin in the short term
and expenditure control.  
"Our plan is to become cash neutral rapidly by focusing almost all of
our efforts and resources on maximizing revenues from tesamorelin in
the near term, while continuing to keep a cap on expenses. By
strengthening our base now, we can better assure our success in the
future and assess opportunities," said Luc Tanguay, President and
Chief Executive Officer. 
Stimulating more potential revenues from tesamorelin  
"Today, we have a great product approved in one major territory and
it is obvious to us that we must spend all of our energy and focus on
getting the most out of it in all territories," stated Mr. Tanguay. 
In support of EMD Serono's efforts, Theratechnologies is working on
incremental improvements to EGRIFTA(TM)'s presentation and
formulation. This includes a new single-vial presentation for which
shipping began in September, the gathering of data in support of
developing a room temperature presentation, and the development of a
more concentrated formulation to be delivered in a smaller syringe.
These improvements should provide EMD Serono with additional tools to
manage the lifecycle of EGRIFTA(TM) in the U.S. 
In an effort to capture new revenue streams from tesamorelin,
Theratechnologies will focus in the next quarters on Brazil and
Europe, the two most important potential markets after the U.S. 
In Brazil, Theratechnologies will work closely with sanofi, its
commercial partner in this territory, to support them in all of their
regulatory activities. As previously announced, technical
deficiencies related to the manufacturing assessment of the Brazil
dossier have been addressed. Also, the assessment of the clinical
portion of the dossier continues to take its course.  
In Europe, Theratechnologies continues to work on identifying options
to resubmit tesamorelin. Discussions with Ferrer Internacional S.A.
(Ferrer), its commercial partner in this territory, are ongoing to
ascertain the most appropriate path to take. By year-end,
Theratechnologies will have completed its assessment of the
resubmission strategy and whether the process will be undertaken by
Ferrer or un-partnered.  
Second generation GRF peptide TH1173 
Theratechnologies will complete the ongoing pre-clinical studies for
its second generation growth hormone-releasing peptide, TH1173, by
year-end, as previously planned. 
The TH1173 clinical program will be financed internally when the
Company generates sufficient additional revenues from tesamorelin. As
it moves forward, the Company may also look to identify and develop
partnership and licensing opportunities in selected territories to
autonomously finance TH1173. 
This approach will ensure that the Company can maintain adequate
liquidities to finance its near-term activities aimed at increasing
revenue potential from tesamorelin while ensuring that the clinical
development of TH1173 will be adequately financed. 
Impact of action plan and measures taken 
The re-alignment of Theratechnologies' priorities in the short term
has led to the suspension of most of its internal long-term R&D
activities, which will impact approximately 15 employees. This will
result in restructuring costs of $5.4 million. This includes $2.5
million in employee compensation (inclusive of the former CEO) and
$2.9 million in non-cash items such as lease and lab equipment
write-offs. Most of these restructuring costs will be registered in
the fourth quarter of 2012.  
In addition, management has agreed to forgo all performance bonuses
for 2012 and, for a second year in a row, has also agreed to a salary
freeze for the next fiscal year.  
"We believe that the action plan we have adopted and the measures we
are putting in place today are in the best interests of our company
and our shareholders," stated Mr. Tanguay. 
Conference Call Details 
A conference call will be held today at 8:45 a.m. ET and hosted by
Luc Tanguay. The conference call will be open to questions from
financial analysts. Media and other interested individuals are
invited to participate in the call on a "listen-only" basis. 
The conference call can be accessed by dialing 1-800-743-9807 (North
America) or 1-416-981-9000 (International). The conference call will
also be accessible via webcast at www.theratech.com. Audio replay of
the conference call will be available until November 13 2012, by
dialing 1-800-558-5253 (North America) or 1-416-626-4100
(International) and by entering the playback code 21609750. 
About Theratechnologies  
Theratechnologies (TSX:TH) (NASDAQ:THER) is a specialty
pharmaceutical company that discovers and develops innovative
therapeutic peptide products, with an emphasis on growth-hormone
releasing factor peptides. Further information about
Theratechnologies is available on the Company's website at
www.theratech.com, on SEDAR at www.sedar.com and on the Securities
and Exchange Commission's website at www.sec.gov.  
Forward-Looking Information  
This press release contains certain statements that are considered
"forward-looking information" within the meaning of applicable
securities legislation, which statements may contain such words as
"may", "would", "could", "will", "intend", "plan", "anticipate",
"believe", "estimate", "expect" and similar expressions. This
forward-looking information includes, but is not limited to,
information regarding the capacity of the Company to become
cash-neutral, to increase its revenue in the short term, to
autonomously finance the clinical development of TH1173, to obtain
the approval of tesamorelin for the treatment of excess abdominal fat
in HIV-infected patients with lipodystrophy in territories where
applications have been filed, to develop a new presentation and new
formulation of EGRIFTA(TM) and to resubmit a marketing authorization
application for tesamorelin in Europe. 
Forward-looking information is based upon a number of assumptions and
is subject to a number of risks and uncertainties, many of which are
beyond Theratechnologies' control that could cause actual results to
differ materially from those that are disclosed in or implied by such
forward-looking information. These assumptions include, but are not
limited to, the fact that we will be able to control our costs and no
unexpected expenses will have to be incurred, our revenues from the
sale of EGRIFTA(TM) in the United States will increase, we will be
able to develop a new presentation and a new formulation of
EGRIFTA(TM) and such improvement will help managing its lifecycle, we
will generate enough revenue to finance the clinical development of
TH1173 or find a partner to do so in selected countries, regulatory
authorities in territories where marketing authorization applications
have been filed will approve tesamorelin for the treatment of excess
abdominal fat in HIV-infected patients with lipodystrophy and, if
approved, tesamorelin will be accepted by the marketplace in these
territories resulting in an increase in revenues for the Company, we
will be able to determine an economically viable strategy to resubmit
a marketing authorization application in Europe for tesamorelin and
European regulatory authorities will approve tesamorelin for
commercialization and we will not be delayed in conducting the
ongoing pre-clinical studies for TH1173. These risks and
uncertainties include, but are not limited to, the risk that we
cannot control our costs due to unforeseen circumstances, that the
revenues generated from the sale of EGRIFTA(TM) in the United States
decrease or remain stable, that EGRIFTA(TM) is subject to a recall or
is withdrawn from the market, that regulatory authorities do not
approve tesamorelin for the treatment of excess abdominal fat in
HIV-infected patients with lipodystrophy for commercial sale in
territories where marketing authorization applications are pending,
that we are unable to develop an economically viable strategy to
resubmit a marketing authorization application in Europe for the
commercial sale of tesamorelin and that, even if submitted in Europe,
the European authorities do not approve tesamorelin for commercial
sale, that we do not have enough revenue to pursue the development of
TH1173 or are unable to find a partner for its development, that the
data gathered do not support the development of a new presentation or
the development of a new formulation and that we are delayed in the
conduct of our ongoing pre-clinical studies for TH1173.  
Theratechnologies refers potential investors to the "Risk Factors"
section of its Annual Information Form (AIF) dated February 27, 2012.
The AIF is available at www.sedar.com and at www.sec.gov under
Theratechnologies' public filings. The reader is cautioned to
consider these and other risks and uncertainties carefully and not to
put undue reliance on forward-looking statements. Forward-looking
information reflects current expectations regarding future events and
speaks only as of the date of this press release and represents
Theratechnologies' expectations as of that date. 
Theratechnologies undertakes no obligation to update or revise the
information contained in this press release, whether as a result of
new information, future events or circumstances or otherwise, except
as may be required by applicable law.
Contacts:
Roch Landriault
NATIONAL Public Relations
Phone: 514-843-2345
 
 
Press spacebar to pause and continue. Press esc to stop.